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Allogeneic hematopoietic cell transplantation is often complicated by graft-versus-host disease (GVHD). We
analyzed the incidences and risk factors for acute (aGVHD) and chronic GVHD (cGVHD), and their impact on
disease relapse and survival, among recipients of single umbilical cord blood (sUCB, n ¼ 295), double um-
bilical cord blood (dUCB, n ¼ 416), and matched sibling donor (MSD, n ¼ 469) allografts. The incidences of
grades II to IV aGVHD and chronic GVHD among dUCB, sUCB, and MSD were 56% and 26%, 26% and 7%, 37%
and 40%, respectively. Development of aGVHD had no effect on relapse, nonrelapse mortality, or overall
survival among cord blood recipients, but it was associated with worse nonrelapse mortality and survival in
MSD recipients. Development of cGVHD was only associated with lower relapse in dUCBT. In multivariate
analysis of GVHD incidence, age > 18 years was associated with higher incidence of aGVHD and cGVHD across
all cohorts. In both UCB cohorts worse HLA match and prior aGVHD were associated with higher risks of
aGVHD and cGVHD, respectively. Nonmyeloablative conditioning limited the risk of aGVHD compared with
myeloablative conditioning in dUCB recipients. Cyclosporine A and mycophenolate mofetil as GVHD pro-
phylaxis lowered the risk of cGVHD, compared with steroids with cyclosporine A, among sUCB recipients. This
large contemporary analysis suggests distiinct risks and consequences of GVHD for UCB and MSD recipients.
Limiting the severity of aGVHD remains important in all groups. Increasing the cord blood inventory or
developing strategies that reduce the cell-dose threshold and thereby increase the chance of identifying an
adequately dosed, better HLA-matched sUCB unit may further limit risks of aGVHD after UCB transplantation.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION recent clinical outcomes approaching, and in certain
Allogeneic hematopoietic stem cell transplantation (allo-
HCT) is a potentially curative treatment modality for a
spectrum of hematologic malignancies, bone marrow failure
syndromes, and inherited metabolic and immune disorders.
For transplantation candidates without a suitable matched
sibling donor (MSD), umbilical cord blood (UCB) has
emerged as an effective alternative donor source with itsedgments on page 139.
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ty for Blood and Marrow Transplantation.circumstances surpassing, those of matched unrelated
donor allografting [1-5]. Despite continued improvements
in outcomes after allo-HCT [6], acute (aGVHD) and chronic
graft-versus-host disease (cGVHD) remain major de-
terminants of post-transplantation morbidity, nonrelapse
mortality (NRM), and health-related quality of life. Even
among recipients of MSD allo-HCT, incidence rates of
aGVHD and cGVHD reach 40% to 50% and 30% to 70%,
respectively [7,8]. Prior studies have suggested important
differences in risk factors for GVHD after UCB trans-
plantation (UBCT) [9,10]. Although the incidence of cGVHD
after single unit UCB transplantation (sUCBT) or double unit
UCB transplantation (dUCBT) was lower than in matched
unrelated donor allo-HCT, despite mismatch in up to 2 HLA
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aGVHD after dUCBT appears to be higher than with sUCBT
[16-18]. Only a few smaller previous studies combining
sUCBT and dUCBT recipients evaluated prognostic factors of
GVHD [19-22], and only 1 of those to our knowledge re-
ported the impact of GVHD on relapse and survival [21].
Existing data on factors that determine acute and chronic
GVHD in dUCBT are incomplete, including the implications
of conventional HLA disparity (ie, antigen-level match at
HLA-A, -B, and allele-level match at -DRB1). We, therefore,
performed a comprehensive analysis of GVHD incidence and
risks factors among sUCB, dUCB, and MSD allograft
recipients with particular focus on HLA disparity and impact
of GVHD on post-transplantation relapse and survival.
METHODS
Study Design
All consecutive patients undergoing their ﬁrst MSD (n¼ 469), sUCB (n¼
295), or dUCB (n ¼ 416) transplantation for a malignant or nonmalignant
condition between 2000 and 2012 were studied. By taking advantage of the
homogeneity in GVHD grading criteria, treatment plans, and graft selection
criteria for MSD and UCB at a single transplantation center, we designed this
study to evaluate the cohort-speciﬁc GVHD outcomes of UCBT in parallel to
the current gold-standard outcomes of MSD allo-HCT. Patient demographic
and clinical informationwere retrieved from the transplantation database at
the University of Minnesota. The primary endpoints were onset of aGVHD
and cGVHD after allo-HCT and their associated risk factors within each in-
dividual cohort. Secondary study endpoints included NRM, disease relapse,
and overall survival (OS), as inﬂuenced by GVHD. The diagnoses of acute and
chronic GVHD were made according to standard clinical criteria [23-25].
HLA disparity and gender mismatch within the dUCB cohort were estab-
lished based on degree of HLA and gender matching between the pre-
dominant cord blood unit of donor and recipient. The cumulative incidences
of aGVHD and cGVHD, along with their risk factors, were assessed within
individual cohorts based on their distinct underlying patient populations.
The analysis of NRM and relapsewas restricted to patients with hematologic
malignancies across all 3 cohorts (MSD, n ¼ 423; sUCB, n ¼ 161; sUCB, n ¼
391). All patients signed informed consent before their transplantation and
this study was approved by the institutional review board at the University
of Minnesota.
Donor Selection, Conditioning Regimens, GVHD Prophylaxis, and
Supportive Care
Our donor selection algorithm conformed to the general practice of
using an HLA-identical sibling as the ﬁrst-choice donor. In the absence of
suitable MSD, a UCB donor graft was frequently used, particularly for pa-
tients with an urgent need for allografting. UCB donor selection was based
on both cell dose and conventional HLA-matching including antigen-level
matching at HLA-A and -B and allele-level matching at HLA-DRB1 as pre-
viously described [26]. A nonmyeloablative conditioning (NMA) regimen
was deﬁned by established criteria [27], and it was used on the basis of
patient age (55 forMSD and45 years for UCB), presence of comorbidities,
and extent of prior therapy. The details of conditioning regimens for MSD
and UCB allograft recipients were previously reported [21,28,29]. In brief,
most patients with hematologic malignancies who underwent myeloa-
blative conditioning (MAC) MSD allo-HCT received cyclophosphamide 120
mg/kg and total body irradiation (TBI) 1320 cGy followed by cyclosporine A
(CsA)/methotrexate or CsA/mycophenolate mofetil (MMF) for GVHD pro-
phylaxis. Most MAC UCBT recipients received cyclophosphamide 120 mg/kg,
ﬂudarabine 75 mg/m2, and TBI 1320 cGy with CsA/MMF used for GVHD
prophylaxis [26]. NoneTBI-based conditioning regimens (17.5%) for MAC
MSD allo-HCT included busulfan/cyclophosphamidee (9%)  antithymocyte
globulin (ATG), ﬂudarabine-based (3%)  ATG, and other less frequent
regimens (5.5%). The NMA regimen for MSD and UCB allo-HCT primarily
consisted of cyclophosphamide (50 mg/kg day 6), ﬂudarabine (30 mg/m2
to 40 mg/m2 day6 through2), and TBI (200 cGy day1)  ATG for those
at higher risk for graft failure because of limited recent chemotherapy [21].
For GVHD prophylaxis, most dUCBT recipients were given CsA andMMF, and
two thirds of sUCBT recipients were given CsA/MMF and one third were
given CsA/methylprednisolone. From 2006 onward, UCBT protocols were
modiﬁed to use a higher MMF dose (3 g/day versus 2 g/day). Stem cell
infusion procedure and post-transplantation supportive care conformed to
our institutional practice guidelines, as previously described [21,26]. All
patients received ﬁlgrastim after allo-HCT until absolute neutrophil count
was 2.5  109/L for 2 consecutive days.Statistical Analysis
Demographic and clinical characteristics were compared across all 3
cohorts by continuous (general Wilcoxon test) and categorical (chi-squared
test) data analyses. The major study outcomes were not directly compared
across the cohorts because each individual cohort had distinct patient
population-, disease-, and transplantation-related characteristics. Instead,
cohort-speciﬁc analyses were conducted throughout the study. Cumulative
incidences of aGVHD and cGVHD were estimated with non-GVHD death or
relapse modeled as competing risks [30]. Fine and Gray proportional haz-
ards regression was used to assess the independent effect of an individual
variable on development of GVHD [31]. Proportional hazard assumptions
were veriﬁed using Martingale residuals. Cox regression analysis was used
in instances when GVHD was treated as a time-dependent covariate in
regression models of secondary endpoints [32]. Regression analyses were
performed in a step-wise fashion, declaring factors with P values < .05 as
statistically signiﬁcant. There was no correction for multiple comparisons.
Confounding factors or variables that showed signiﬁcance across similar
endpoints or subgroups may have also been included in the ﬁnal models.
Factors tested in regression models included age, disease risk, conditioning
regimen (MAC versus NMA), donor/recipient cytomegalovirus serostatus,
donor-recipient gender match (female-to-male versus other), year of
transplantation (<2006 versus 2006), GVHD prophylaxis, ATG use, and
stem cell source (marrow versus peripheral blood) for MSD. Disease risks at
the time of allo-HCT for patients with hematologic malignancies were
classiﬁed as standard (ie, acute leukemia in ﬁrst or second complete
remission, chronic myeloid leukemia in ﬁrst chronic phase, Hodgkin or
non-Hodgkin lymphoma in complete or partial chemotherapy sensitive
remission, chronic lymphoid leukemia in ﬁrst remission, myelodysplastic
syndrome or myeloproliferative neoplasmwithout excess blasts) or high (all
other conditions) risks based on the America Society for Blood and Marrow
Transplantation 2006 risk-scoring schema (http://www.asbmt.org). All
statistical analyses were performed with SAS 9.3 (SAS Institute, Cary, NC)
and R 3.0.2.RESULTS
Patient and Clinical Characteristics across All Cohorts
Patient and transplantation-speciﬁc characteristics in all
3 cohorts are detailed in Table 1. Although sUCBT recipients
were younger, the median ages of MSD and dUCB allograft
recipients were comparable. Gender mismatched allografts
were balanced among all cohorts, but recipients of sUCB,
dUCB, and MSD differed from each other according to con-
ditioning intensity (myeloablative in 82%, 42%, 55%, respec-
tively), GVHD prophylaxis (CsA þ MMF in 66%, 99%, 48%,
respectively), use of ATG, underlying diagnosis, and disease
risk. The dUCBT cohort was also enriched with recipients of
4/6 HLAemismatched engrafted units compared with the
sUCBT cohort. The median follow-up for survivors across all
cohorts exceeded 5 years. In addition, we observed distinct
patterns of organ-speciﬁc involvement by aGVHD and
cGVHD across all cohorts (Supplemental Figure 1).Incidence and Risk Factors of aGVHD
The cumulative incidences (100 days) of grade II to IV
were 37% (MSD), 26% (sUCB), and 56% (dUCB), and the
cumulative incidences (100 days) of grade III and IV aGVHD
were 16% (MSD), 7% (sUCB), and 21% (dUCB) (Figure 1).
Cohort-speciﬁc multivariate analyses of aGVHD risks are
shown in Table 2.
MSD cohort
Both older age and peripheral blood stem cell (PBSC)
grafts were associated with a higher risk of aGVHD. Owing to
the signiﬁcant correlation between age and graft source, we
report the data for graft source stratiﬁed by age. Older re-
cipients of PBSC grafts had signiﬁcantly higher incidence
rates of grade II to IV (hazard ratio [HR], 3.7, 95% conﬁdence
interval [CI], 1.8 to 7.6) aGVHD (Table 3) compared with
younger patients. The use of NMA allo-HCT with (HR, 2.9;
95% CI, 1.4 to 5.8) or without ATG (HR, 2.1; 95% CI, 1.2 to 3.7)
Table 1
Patient and Clinical Characteristics
Variables MSD
(n ¼ 469)
sUCB
(n ¼ 295)
dUCB
(n ¼ 416)
Age, median (range), yr 46.9 (0-74) 8.1 (0-65) 43.9 (1-72)
<18 83 (17.7) 232 (78.6) 64 (15.4)
Gender
Male 290 (61.8) 159 (53.9) 261 (62.7)
Female-to-male
mismatch
133 (28.4) 74 (25.1) 128 (30.8)
Year of allo-HCT
2000-2005 242 (51.6) 154 (52.2) 156 (37.5)
2006-2012 227 (48.4) 141 (47.8) 260 (62.5)
Diagnosis
Nonmalignant 46 (9.8) 134 (45.4) 25 (6)
Leukemia*/MDS/MPN 257 (54.8) 133 (45.1) 293 (70.4)
Lymphomay/CLL/other 166 (35.4) 28 (9.5) 98 (23.6)
Disease riskz
Standard 224 (47.8) 113 (38.3) 250 (60.1)
High-risk 199 (42.4) 48 (16.3) 141 (33.9)
CMV seropositive
recipient
260 (55.4) 133 (45.1) 233 (56)
Conditioning regimen
MAC 260 (55.4) 242 (82) 173 (41.6)
NMA 209 (44.6) 53 (18) 243 (58.4)
ATG (with conditioning) 77 (16.4) 175 (59.3) 95 (22.8)
GVHD prophylaxis
CsA þ MMF 224 (47.8) 194 (65.8) 411 (98.8)
CsA þ methotrexate 245 (52.2) 0 0
CsA þ steroid  ATG 0 101 (34.2) 5 (1.2)
HLA disparityx
6/6 469 (100) 66 (22.4) 46 (11.1)
5/6 0 147 (49.8) 183 (44)
4/6 0 82 (27.8) 187 (45)
TNC, median (range), 
108/kg
7.7 (1-31) .5 (0-5) .4 (0-5)
Follow-up time, median
(range), mo
72.4 (.4-171) 63.7 (.5-171) 67.5 (.2-149)
MDS indicates myelodysplastic syndromes; MPN, myeloproliferative neo-
plasms; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; TNC,
total nucleated cells.
Data presented are n (%), unless otherwise indicated.
* Includes acute myeloid leukemia, acute lymphoblastic leukemia, and
chronic myeloid leukemia.
y Includes Hodgkin and Non-Hodgkin lymphomas.
z According to ASBMT 2006 deﬁnitions; remaining percent corresponds
to nonmalignant disorders.
x Based on HLA matching between the predominant cord unit and
recipient.
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aGVHD compared with that of MAC allo-HCT. We further
explored the independent effect of conditioning intensity on
aGVHD and found that NMA conditioning signiﬁcantly
increased aGVHD risk, even after restricting the analysis to
PBSC recipients (HR, 2.2; P < .01 for NMA [n ¼ 190] versus
MAC [n ¼ 177]).
sUCB cohort
In the multivariate analysis, age 18 years was associated
with higher incidence of grade II to IV aGVHD (HR, 1.9; P ¼
.01) and grade III and IV aGVHD (HR, 3.4; P< .01). Worse HLA
match inﬂuenced development of grade II to IV aGVHD with
higher incidence among recipients of a 4/6- to 5/6-matched
cord blood unit (HR, 1.9 for 5/6; HR, 1.9 for 4/6; all P  .05)
compared with those with 6/6 match. No association was
found between HLA disparity and risk of grade III and IV
aGVHD. No other factors inﬂuenced the incidence of aGVHD.
dUCB cohort
In the multivariate analysis, the use of ATG with NMA
allo-HCT (HR, .5; 95% CI, .3 to .7), and transplantationperformed after 2006 (HR, .6; 95% CI, .5 to .8) were associated
with lower risks of grade II to IV aGVHD, whereas age  18
years was associated with higher risks (HR, 1.6; 95% CI, 1.0 to
2.4). Greater HLAmismatch was associated with greater risks
of grade III and IV aGVHD (HR, 2.5; 95% CI, .9 to 6.9 for 5/6
versus HR, 2.8; 95% CI, 1.0 to 7.7 for 4/6 versus 6/6 match).
NMA conditioning with ATG (HR, .5; 95% CI, .3 to 1.0) or
without ATG (HR, .6; 95% CI, .4 to 1.0) led to lower risks of
grade III and IV aGVHD compared to MAC. There was a sig-
niﬁcant overlap in the use of ATG (total n ¼ 95) and NMA
allo-HCT (n ¼ 82 with ATG). However, even among ATG-free
dUCB NMA allografts, therewas a trend towards less grade III
and IV aGVHD and cGVHD.Risk Factors for cGVHD
The cumulative incidences of cGVHD (2 years) were 40%
(MSD), 7% (sUCB), and 26% (dUCB) (Figure 1). Cohort-speciﬁc
univariate and multivariate analyses of cGVHD risks are
outlined in Table 2.
MSD cohort
In competing risk multivariate analysis, only age and graft
source predicted onset of cGVHD, and older recipients of
either marrow (HR, 4.8; 95% CI, 1.2 to 18.2) or PBSC (HR, 10;
95% CI, 3.3 to 30.4) grafts had a higher incidence of cGVHD.
No other variables were associated with cGVHD.
sUCB cohort
After including grade II to IV aGVHD as a time-dependent
covariate in the multivariate Cox regression, older age (HR,
5.7; 95% CI, 1.9 to 16.5) was associated with higher incidence
of cGVHD, whereas prophylaxis with CsA þ MMF was asso-
ciated with a lower incidence of cGVHD (HR, .3; 95% CI, .1 to
.9 versus CsA þ steroid). Prior history of grade II to IV aGVHD
also increased the risk of cGVHD (HR, 2.4; 95% CI, 1.0 to 6.0),
whereas HLA disparity did not inﬂuence risk of cGVHD.
dUCB cohort
In the multivariate analysis, prior grades II to IV aGVHD
(HR, 2.0; 95% CI, 1.3 to 3.2), as a time-dependent covariate,
and older age (HR, 5.4; 95% CI, 2.1 to 13.7) were associated
with higher incidence of cGVHD (Table 2). HLA disparity had
no appreciable inﬂuence on development of cGVHD.Impact of GVHD on NRM and Relapse
MSD cohort
Two-year NRM for MSD allo-HCT was 22% (95% CI, 18% to
26%). In multivariate analysis, grades II to IV (HR, 2.1; 95% CI,
1.3 to 3.2; P< .01) and grades III and IV (HR, 3.8; 95% CI, 2.4 to
6.0; P< .01) aGVHD, but not cGVHD (HR, 1.8; 95% CI, .9 to 3.4;
P ¼ .43) were associated with higher 2-year NRM (Table 3).
Probability of disease relapse within 2 years from allo-HCT
was 27% (95% CI, 23% to 31%). There was no association be-
tween aGVHD (any grade) or cGVHD and relapse (all P > .10).
sUCB cohort
Cumulative incidence of 2-year NRM for sUCB allograft
recipients was 21% (95% CI, 15% to 27%). Neither incidence of
aGVHD nor cGVHD had a signiﬁcant impact on NRM (all P >
.10). The probability of disease relapse within 2 years after
allo-HCT was 29% (95% CI, 22% to 36%) and was not
inﬂuenced by aGVHD or cGVHD (all P > .70).
Figure 1. Cumulative incidence of GVHD by donor type. (A) Shows cumulative incidence of aGHVD grades II to IV. (B) Shows cumulative incidence of a GVHD grades
III and IV. (C) shows cumulative incidence of cGVHD.
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Cumulative incidence of 2-year NRM for dUCB allograft
recipients was 23% (95% CI, 19% to 27%). Neither grades II to
IV nor grades III and IV aGVHD had an impact on NRM.
Similarly, the development of cGVHD had no signiﬁcant
inﬂuence on NRM (HR, 1.4; 95% CI, .7 to 2.7; P ¼ .40). Cu-
mulative risk of relapsewithin 2 years after allo-HCTwas 31%
(95% CI, 27% to 35%). Although relapse risk was not affected
by grades II to IV or grades III and IV aGVHD, it was signiﬁ-
cantly reduced by development of cGVHD (HR, .5; 95% CI, .3
to .9; P ¼ .03) in the multivariate analysis.
Impact of GVHD on OS
MSD cohort
Two-year OS was 60% (95% CI, 55% to 64%) for the entire
cohort. Grade II to IV (HR, 1.6; 95% CI, 1.2 to 2.2; P < .01) and
grades III and IV (HR,1.9; 95% CI,1.3 to 2.7, P< .01) aGVHD but
not cGVHD (HR, .8; 95% CI, .5 to 1.3; P ¼ .40), were associated
with inferior OS in the multivariate analysis (Table 3).
sUCB cohort
In the entire cohort, OS at 2 years from allo-HCT was 64%
(95% CI, 58% to 69%). Onset of grades II to IV aGVHD or cGVHD
had no impact on OS in the entire cohort. Grades III and IV
aGVHD trended to an association with higher mortality (HR,
1.8; 95% CI, 1.0 to 3.3; P ¼ .06) among all patients.
dUCB cohort
OS at 2 years from allo-HCT was 56% (95% CI, 51% to 60%).
Neither aGVHD nor cGVHD were prognostic for OS, and no
other signiﬁcant predictors of OS were identiﬁed in multi-
variate analysis.
DISCUSSION
GVHD compromises the effectiveness of potentially
curative HCT therapy for patients with life-threatening blood
disorders. The preferred use of an HLA-identical sibling
donor has emerged in part because of better donor-recipient
histocompatibility and consequently less GVHD compared
with those after the use of an unrelated donor. However, thenecessity of stringent HLA matching has been successfully
challenged by unrelated and usually partially HLA mis-
matched UCBT, with its major outcomes rivaling those after
matched related and unrelated donor allo-HCT [1-5,14,29,33-
35]. Our analysis has focused on establishing the incidence
and prognostic determinants of acute and chronic GVHD in
UCBT in parallel to benchmark MSD allo-HCT. Our observed
lower incidence of cGVHD in both sUCBT and dUCBT and
higher incidence of grades II to IV aGVHD in dUCBT is
consistent with several prior studies [15,19,22,36-38].
Notably, despite a higher overall incidence of aGVHD in the
dUCB cohort, aGVHD had no impact on 2-year NRM, relapse,
or OS in the present study. This ﬁnding is in contrast to MSD,
where aGVHD was associated with higher NRM and lower
OS. This could be, in part, related to higher responsiveness
among UCBT recipients with aGVHD to upfront therapy with
systemic corticosteroids [39]. The results of our analysis of
risk factors for cGVHD are also in agreement with prior
studies demonstrating older age (all 3 cohorts) and use of
PBSC graft (MSD cohort) to be associated with higher risk of
cGVHD [7,16].
Historically, the lower incidence of cGVHD in UCBT has
hampered investigation of prognostic determinants of
cGVHD in multiple prior studies, most of which had fewer
patients compared with ours. This study, because of its pri-
mary focus on GVHD incidence and risks, included broad
populations of sibling donor and cord blood allograft
recipients, including a large population of dUCBT recipients.
By setting the MSD cohort as a reference, we provided
comparative results of incidence and impact of aGVHD and
cGVHD on outcomes after UCBT.
Other noteworthy ﬁndings from our study pertain to risk
factors of aGVHD and cGVHD. Similar to our results, use of
ATG as part of the conditioning or GVHD prophylaxis also has
been shown to be associated with lower incidence of grades
II to IV aGVHD in dUCBT [5,21,22]. In our study, all patients in
the dUCBT cohort receiving ATG underwent an NMA allo-
HCT, with a lower risk of aGVHD being possibly inﬂuenced
by both factors. Surprisingly, however, in the MSD cohort we
found a higher risk of grades II to IV aGVHD associated with
Table 3
Time-Dependent Impact of GVHD on Two-Year NRM, Relapse, and OS
Cohort/GVHD NRM Relapse OS*
95% CI P 95% CI P 95% CI P
MSD
Grade II-IV
aGVHD
2.1 (1.3-3.2) <.01 1.3 (.9-1.8) .21 1.6 (1.2-2.2) <.01
Grade III-IV
aGVHD
3.8 (2.4-6.0) <.01 1.0 (.6-1.7) .93 1.9 (1.3-2.7) <.01
cGVHD 1.8 (.9-3.4) .43 .6 (.4-1.2) .14 .8 (.5-1.3) .40
sUCB
Grade II-IV
aGVHD
1.1 (.5-2.2) .78 1.0 (.5-2.2) .93 1.2 (.8-1.8) .51
Grade III-IV
aGVHD
1.1 (.4-3.3) .85 .8 (.2-2.6) .72 1.8 (1.0-3.3) .06
cGVHD 3.5 (.7-18.5) .14 .8 (.2-3.5) .75 1.4 (.5-3.6) .50
dUCB
Grade II-IV
aGVHD
.8 (.5-1.2) .31 .8 (.6-1.2) .29 .9 (.7-1.2) .49
Grade III-IV
aGVHD
1.2 (.7-1.9) .55 .8 (.5-1.3) .41 1.1 (.8-1.6) .49
cGVHD 1.3 (.6-2.7) .46 .5 (.3-.9) .03 .9 (.5-1.4) .51
Bolded estimates denote differences with P < .05.
All estimates were derived from the multivariate models adjusted for pa-
tient age, stem cell source, recipient cytomegalovirus serostatus, HLA
disparity, conditioning intensity, year of transplantation, and disease risk, as
necessary.
* Estimates for OS correspond to relative risk of death from any cause.
Table 2
Cohort-Speciﬁc Risk Factors of GVHD: Multivariate Regression Analysis
Cohort/Risk Factor Relative Risk (95% CI)
aGVHD II-IV aGVHD III-IV cGVHD
MSD
Graft source/age
BM þ PBSC/<18 1.0 1.0 1.0
BM/18 2.0 (.7-5.7) 1.0 (.1-7.9) 4.8 (1.2-18.2)
PBSC/18 3.7 (1.8-7.6) 2.7 (.8-8.9) 10.0 (3.3-30.4)
Disease risk
Standard 1.0 1.0 1.0
High 1.0 (.7-1.4) 1.1 (.7-1.8) 1.0 (.8-1.4)
Nonmalignant .3 (.1-1.1) .3 (.4-1.9) .6 (.2-2.2)
Conditioning
MAC 1.0 1.0 1.0
NMA (þATG) 1.1 (.7-1.8) 2.9 (1.4-5.8) .9 (.5-1.4)
NMA (ATG) .9 (.7-1.3) 2.1 (1.2-3.7) 1.2 (.9-1.6)
aGVHD II-IV* NA NA
No 1.0
Yes 1.1 (.8-1.4)
sUCB
Age
<18 1.0 1.0 1.0
18 1.9 (1.2-3.0) 3.4 (1.6-7.2) 5.7 (1.9-16.5)
HLA disparity
6/6 1.0 1.0 1.0
5/6 1.9 (1.0-3.9) .8 (.2-2.4) .6 (.2-2.2)
4/6 1.9 (.9-4.0) 1.0 (.3-3.2) 1.1 (.3-4.0)
GVHD prophylaxis
CsA þ steroid 1.0 1.0 1.0
CsA þ MMF .9 (.5-1.4) .4 (.2-1.1) .3 (.1-.9)
aGVHD II-IV* NA NA
No 1.0
Yes 2.4 (1.0-6.0)
dUCB
Age
<18 1.0 1.0 1.0
18 1.6 (1.0-2.4) 1.3 (.7-2.5) 5.4 (2.1-13.7)
HLA disparity
6/6 1.0 1.0 1.0
5/6 1.1 (.7-1.7) 2.5 (.9-6.9) .9 (.4-1.8)
4/6 1.1 (.7-1.7) 2.8 (1.0-7.7) 1.3 (.7-2.7)
Conditioning
MAC 1.0 1.0 1.0
NMA (þATG) .5 (.3-.7) .5 (.3-1.0) .7 (.4-1.1)
NMA (ATG) .8 (.6-1.1) .6 (.4-1.0) .7 (.5-1.1)
Year of allo-HCT
<2006 1.0 1.0 1.0
2006 .6 (.5-.8) .8 (.5-1.2) .9 (.6-1.3)
aGVHD II-IV* NA NA
No 1.0
Yes 2.0 (1.3-3.2)
BM indicates bone marrow; NA, not available.
Bolded estimates denote differences with P  .05.
* Time-dependent covariate.
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explained by the older age of the recipients and more
frequent use of PBSC sourcewith NMA allo-HCT in our center
(n¼ 192, 91%). HLAmismatch is a well-recognized risk factor
associated with higher incidence of grades II to IV aGVHD
after unrelated donor HCTas well as after sUCBT with the use
of either high resolution [16] or conventional typing
[16,40,41]. Our study has now provided further conﬁrmation
of these results in the setting of dUCBT while utilizing con-
ventional HLA-matching. Although our observed association
between donor-to-recipient HLAmatching and grades II to IV
aGVHD after sUCBTcorroborate earlier studies [16,40,41], the
impact of conventional HLA matching on onset of severe
aGVHD after dUCBT is a unique ﬁnding. Moreover, it is
consistent with another recent analysis, where better allele-
level HLA match between engrafted cord blood unit and therecipient predicted lower incidence of severe aGVHD [39]. In
concert with other reports [15,19], we identiﬁed older age as
an independent predictor of more frequent grades II to IV
aGVHD across all 3 cohorts. Furthermore, UCB allograft re-
cipients over 18 years old were at signiﬁcantly higher risk for
development of cGVHD in all adjusted models. Although a
similar association between older age and higher risk of
cGVHD was previously reported in the COBLT study of pe-
diatric sUCB recipients [16], our study is the ﬁrst to establish
the signiﬁcance of recipient age as a predictor of cGVHD in
dUCBT. Finally, in our analysis, dUCBT procedures performed
after 2005 were 40% less likely to be associated with grades II
to IV aGVHD. This observation can be most probably
explained by the change in our clinical practice of using a
higher MMF dose (3 g after 2006 versus 2 g in the past) for
GVHD prophylaxis. This resulted in a signiﬁcant risk reduc-
tion of grades II to IV acute GVHD as demonstrated recently
by our group [42].
The use of sUCB, dUCB, or MSD (bone marrow versus
peripheral blood) sources of hematopoietic stem cells often
involves prespeciﬁed package of distinct patient-, disease-,
and allo-HCTerelated factors that limit the ability of this
study and others to delineate the true association between
the donor source and GVHD outcomes. We attempted to
eliminate this bias by focusing on cohort-speciﬁc associa-
tions and by foregoing direct comparison in GHVD incidence
and risks between the cohorts.
In summary, this large analysis of contemporary
cohorts establishes the incidence and prognostic
determinants of GVHD for UCB in parallel to benchmark
MSD allo-HCT. Our data argue that better HLA match may
further mitigate the risks of grades III and IV aGVHD and
thereby maximize the beneﬁts of dUCBT. Increasing the
UCB inventory or developing strategies that reduce the
cell-dose threshold and thereby increase the chance of
identifying an adequately dosed, better HLA-matched
single UCB unit would further limit risks of acute GVHD
after UCB transplantation.
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